Oxford Biomedica plc (LON:OXB) shares reached a new 52-week high on Wednesday . The company traded as high as GBX 1,628 ($21.27) and last traded at GBX 1,549.15 ($20.24), with a volume of 50236 shares trading hands. The stock had previously closed at GBX 1,478 ($19.31).
The company has a quick ratio of 1.88, a current ratio of 2.06 and a debt-to-equity ratio of 12.28. The firm has a market capitalization of £1.28 billion and a price-to-earnings ratio of -189.49. The company has a 50-day moving average price of GBX 1,403.37 and a 200-day moving average price of GBX 1,215.76.
Oxford Biomedica Company Profile (LON:OXB)
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.